Skip to content

What's new

Every change, dated.

When a dose, a source or an FDA status changes, the page logs it. This is all of those logs in one place, newest first.

Follow the feed

    • Peptide

      Adamax: Set the FDA status to not evaluated: no approval, no trials program, and not named on FDA's 503A or 503B category lists, now cited directly.

    • Peptide

      Adipotide: First published.

    • Peptide

      AHK-Cu: First published.

    • Peptide

      AOD-9604: Added an answer-first summary.

    • Peptide

      AOD-9604: Backed the 12 to 0 committee vote with a quote from FDA's December 4, 2024 minutes, and relabelled news, trade group and company sources so they no longer pass as regulator pages.

    • Peptide

      AOD-9604: Dropped a dead law-firm link (Reed Smith) from the FDA status and backed the 2023 Category 2 placement and 2024 removal with FDA's own category lists; changed the HGH fragment link to its canonical slug hgh-fragment-176-191.

    • Peptide

      ARA-290: First published.

    • Peptide

      ARA-290: FDA status now reads 503A Category 3 (nominated without adequate support), the list FDA places cibinetide on; its orphan designations stay in the text.

    • Peptide

      BPC-157: Checked the July 2026 advisory committee vote counts: FDA has posted no minutes, so they stay marked as reported and cite the press report.

    • Peptide

      BPC-157: Replaced law-firm summaries behind the FDA status with FDA's own category lists, safety-risk page and July 2026 advisory committee page, and corrected the Category 2 removal date to April 22, 2026 (FDA posted the notice on April 15).

    • Peptide

      BPC-157 + TB-500 blend: Checked the July 2026 advisory committee vote counts: FDA has posted no minutes, so they stay marked as reported and cite the press report.

    • Peptide

      BPC-157 + TB-500 blend: Replaced law-firm summaries behind the FDA status with FDA's own category lists, safety-risk page and July 2026 advisory committee page, and corrected the Category 2 removal date to April 22, 2026 (FDA posted the notice on April 15).

    • Peptide

      Cagrilintide: Investigational status now rests on the REDEFINE 1 registry entry. Filing news is marked second-hand, trial news is labelled a study report, and the expected Q4 2026 decision is labelled a guide projection, so the approval FAQ reads Reference.

    • Peptide

      CagriSema: First published.

    • Peptide

      Cartalax: First published.

    • Peptide

      Cerebrolysin: First published.

    • Peptide

      CJC-1295: Added an answer-first summary.

    • Peptide

      Dihexa: First published.

    • Peptide

      DSIP: Replaced a law-firm write-up on the FDA status, FAQ and epitalon comparison with FDA's April 2026 category list and the RAPS report of the July 2026 votes; the law firm stays only as a media source.

    • Peptide

      DSIP: Marked the July 2026 committee tally as reported, since FDA has not posted minutes, and replaced a trade group copy of FDA's 2023 category list with an archived copy of FDA's own file.

    • Peptide

      Eloralintide: First published.

    • Peptide

      Epitalon: Marked the July 2026 committee tally as reported, since FDA has not posted minutes, and labelled the trade press sources behind it as news reports of an FDA meeting.

    • Peptide

      Epitalon: Replaced law-firm summaries behind the FDA status with FDA's own category lists, safety-risk page and July 2026 advisory committee page, and corrected the Category 2 removal date to April 22, 2026 (FDA posted the notice on April 15).

    • Peptide

      Follistatin 344: First published.

    • Peptide

      FOXO4-DRI: Moved the 2017 mouse dose out of the dose protocols into the mouse-dosing FAQ and the evidence summary, so no calculator can treat it as a human dose.

    • Peptide

      FOXO4-DRI: First published.

    • Peptide

      GHK-Cu: Dropped a clinic's 503A status tracker from the FDA sources; FDA's own category lists already back every status fact.

    • Peptide

      GHK-Cu: Replaced the law-firm summary behind the FDA status with FDA's own lists, and updated the status: non-injectable GHK-Cu was put back in 503A Category 1 in May 2026, while injectable GHK-Cu stays off Category 2 after withdrawn nominations (removed April 22, 2026).

    • Peptide

      GHRP-2 and GHRP-6: Set the FDA status to Category 2 on FDA's 503B list (GHRP-6, and GHRP-2 for injection or nasal use), cited the 503B list directly, and stated that FDA's 503A list has both in Category 3.

    • Peptide

      GLOW: Checked the July 2026 advisory committee vote counts: FDA has posted no minutes, so they stay marked as reported and cite the press report.

    • Peptide

      GLOW: Replaced law-firm summaries behind the FDA status with FDA's own category lists, safety-risk page and July 2026 advisory committee page, and corrected the Category 2 removal date to April 22, 2026 (FDA posted the notice on April 15).

    • Peptide

      Glutathione: First published.

    • Peptide

      Gonadorelin: First published.

    • Peptide

      Hexarelin: First published.

    • Peptide

      HGH Fragment 176-191: First published.

    • Peptide

      Humanin: Moved the two mouse doses out of the dose protocols into the mouse-dosing FAQ and the evidence summary, and marked the evidence as animal-only, since no trial has given humanin to people.

    • Peptide

      Humanin: First published.

    • Peptide

      Ipamorelin: Added an answer-first summary.

    • Peptide

      Kisspeptin: First published.

    • Peptide

      KLOW: Added an answer-first summary.

    • Peptide

      KLOW: Checked the July 2026 advisory committee vote counts: FDA has posted no minutes, so they stay marked as reported and cite the press report.

    • Peptide

      KLOW: Replaced law-firm summaries behind the FDA status with FDA's own category lists, safety-risk page and July 2026 advisory committee page, and corrected the Category 2 removal date to April 22, 2026 (FDA posted the notice on April 15).

    • Peptide

      KPV: Checked the July 2026 advisory committee vote counts: FDA has posted no minutes, so they stay marked as reported and cite the press report.

    • Peptide

      KPV: Replaced law-firm summaries behind the FDA status with FDA's own category lists, safety-risk page and July 2026 advisory committee page, and corrected the Category 2 removal date to April 22, 2026 (FDA posted the notice on April 15).

    • Peptide

      Liraglutide: First published.

    • Peptide

      LL-37: First published.

    • Peptide

      Mazdutide: First published.

    • Peptide

      Melanotan 1: First published.

    • Peptide

      Melanotan II: Added an answer-first summary.

    • Peptide

      Melanotan II: First published.

    • Peptide

      MK-677 (Ibutamoren): First published.

    • Peptide

      MOTS-c: Added an answer-first summary.

    • Peptide

      MOTS-c: Moved the CB4211 analog trial dose out of the dose table (it stays in the FAQ and evidence summary), marked the evidence as animal only, and marked the July 2026 committee tally as reported, since FDA has not posted minutes.

    • Peptide

      MOTS-c: Replaced law-firm summaries behind the FDA status with FDA's own category lists, safety-risk page and July 2026 advisory committee page, and corrected the Category 2 removal date to April 22, 2026 (FDA posted the notice on April 15).

    • Peptide

      N-Acetyl Selank Amidate: First published.

    • Peptide

      N-Acetyl Semax Amidate: First published.

    • Peptide

      NAD+: Replaced a law-firm summary of the NMN supplement decision with FDA's own September 29, 2025 response letter.

    • Peptide

      Oxytocin: Replaced the 500 IU per mg conversion, which came from a vendor and a guide, with the 600 IU per mg in the European Pharmacopoeia oxytocin monograph, backed by the WHO International Standard. The vendor figure is kept as a noted disagreement.

    • Peptide

      Oxytocin: First published.

    • Peptide

      P21: First published.

    • Peptide

      PE-22-28: First published.

    • Peptide

      PEG-MGF: First published.

    • Peptide

      Pinealon: First published.

    • Peptide

      Retatrutide: Added an answer-first summary.

    • Peptide

      Retatrutide: News on Lilly's filing plan and early access program is now labelled as media, since those are company plans, not FDA actions, so the approval FAQ reads Media report. The GLP-3 FAQ reads Reference. The investigational status rests on the trial registry.

    • Peptide

      Retatrutide: Added FAQs on drinking alcohol, how often to take it and when it is coming out, with Lilly's Q1 2027 filing plan checked against news on October 24, 2026.

    • Peptide

      Retatrutide: Added FDA's own August 2026 warning letter for the point that a research use only label does not protect a seller; the law-firm alert stays only as a media source.

    • Peptide

      Selank: selank.ru is down, so its label, FAQ and pharmacokinetics pages are now cited through Internet Archive copies that still show the same facts.

    • Peptide

      Selank: selank.ru label copies are now marked as coming from the maker, the maker's alcohol claim is labelled as such, and side effects, half-life and the registration number also cite the label on Vidal (now ЛП-№(010951)-(РГ-RU), previously ЛСР-003338/09).

    • Peptide

      Selank + Semax blend: First published.

    • Peptide

      Semaglutide: Wegovy HD and Wegovy tablet doses now cite the DailyMed label with the exact dosing text, and their approval dates cite Drugs@FDA instead of news reports. The dosing-error warning cites FDA's own alert. News and drug-guide pages that repeat FDA or WADA facts are marked as second-hand.

    • Peptide

      Semax: Vote counts stay marked as reported (FDA has posted no minutes). Russian label doses, side effect and contraindications now also cite the label on Vidal; the optic nerve course is 7 to 10 days per the current label.

    • Peptide

      Semax: Added the July 2026 advisory committee outcome (8 to 5 to recommend, per RAPS) and FDA's April 22, 2026 removal from Category 2.

    • Peptide

      Sermorelin: Kept the withdrawn status and backed it with the 2009 Federal Register notice in which FDA withdrew both Geref approvals at the maker's request, added the Drugs@FDA pages, and noted the 503B Category 1 listing.

    • Peptide

      SLU-PP-332: First published.

    • Peptide

      SNAP-8: First published.

    • Peptide

      Somatropin (HGH): First published.

    • Peptide

      SS-31: Added an answer-first summary.

    • Peptide

      Survodutide: First published.

    • Peptide

      TB-500: Added an answer-first summary.

    • Peptide

      TB-500: Linked the new full-length thymosin beta-4 page as a separate variant.

    • Peptide

      TB-500: Checked the July 2026 advisory committee vote counts: FDA has posted no minutes, so they stay marked as reported and cite the press report.

    • Peptide

      TB-500: Replaced law-firm summaries behind the FDA status with FDA's own category lists, safety-risk page and July 2026 advisory committee page, and corrected the Category 2 removal date to April 22, 2026 (FDA posted the notice on April 15).

    • Peptide

      Thymalin: First published.

    • Peptide

      Thymosin Alpha-1: First published.

    • Peptide

      Thymosin beta-4: First published.

    • Peptide

      Tirzepatide: Added an answer-first summary.

    • Peptide

      Tirzepatide: Mounjaro and Zepbound sleep apnea doses now cite the label text directly instead of Lilly's medical pages, approval dates cite Drugs@FDA instead of Wikipedia, and news pages repeating FDA or WADA facts are marked second-hand.

    • Peptide

      Tirzepatide: SeekPeptides is an education site, not a seller: its figures now read as a competitor guide.

    • Peptide

      Tirzepatide: Replaced dead vendor links behind the vial sizes and the GLP-2 FAQ with live guides (vial sizes now read Competitor guide), and replaced law-firm summaries of the shortage and compounding rules with FDA's own December 2024 order, guidance and March 2026 warning letter release.

    • Peptide

      VIP: First published.

    • Guide

      Bacteriostatic water vs sterile water for peptides: First published.

    • Guide

      mg to units: how to convert a peptide dose to syringe units: SeekPeptides is an education site, not a seller: its figures now read as a competitor guide.

    • Guide

      Peptide cycling and rest periods: selank.ru is down, so its label, FAQ and pharmacokinetics pages are now cited through Internet Archive copies that still show the same facts.

    • Guide

      Peptide dosing chart: every compound, by category: SeekPeptides is an education site, not a seller: its figures now read as a competitor guide.

    • Guide

      Peptide storage: powder, mixed vials, fridge, freezer and travel: SeekPeptides is an education site, not a seller: its figures now read as a competitor guide.

    • Guide

      Retatrutide units chart: doses in units for every common vial: First published.

    • Guide

      Tirzepatide units chart: how many units is 2.5, 5, 10 or 15 mg?: First published.

    • Guide

      What size syringe and needle for peptides: First published.

    • Guide

      Where to inject peptides: belly, thigh, arm or glute: First published.

    Glossary

    1 term updated: FDA Category 2

  2. Glossary

    39 terms updated: 503A vs 503B, Alcohol swab, Bacteriostatic water, Certificate of analysis (COA), Cold chain, Compounded vs branded, Cycle, Dead space, Draw, Endotoxin, GHRH, GHRP, GIP, GLP-1, Glucagon receptor, Half-life, HPLC purity, Injection site rotation, Insulin pen vs vial, Intramuscular injection, Loading dose, Lyophilized, Mass spectrometry, Microdosing, Needle gauge, Net peptide content, Peptide blend, Peptide stability, Reconstitution, Research use only (RUO), Secretagogue, Sterile technique, Subcutaneous injection, Titration, U-100 insulin syringe, Units vs mg vs mcg, Vial headspace, WADA S0, Washout